Presentation is loading. Please wait.

Presentation is loading. Please wait.

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study 

Published byJorge Hidalgo Modified over 5 years ago

Similar presentations

Presentation on theme: "Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study "— Presentation transcript:

1 Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study  Hiroyuki Sakurai, MD, Hisao Asamura, MD, Tomoyuki Goya, MD, Kenji Eguchi, MD, Yoichi Nakanishi, MD, Noriyoshi Sawabata, MD, Meinoshin Okumura, MD, Etsuo Miyaoka, PhD, Yoshitaka Fujii, MD  Journal of Thoracic Oncology  Volume 5, Issue 10, Pages (October 2010) DOI: /JTO.0b013e3181f1923b Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Distribution of histologic types between men and women. AD, adenocarcinoma; SQ, squamous cell carcinoma; LG, large cell carcinoma; AS, adenosquamous cell carcinoma. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Overall survival curves based on gender. The 5-year survival rates of female (n = 4091) and male (n = 8008) patients are 75.6 and 57.9%, respectively. The difference in survival between the genders is significant (p = ). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Overall survival curves according to gender in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for adenocarcinoma is 61.9% for male patients and 77.7% for female patients. The difference in survival is significant (p = ). The 5-year survival rate for nonadenocarcinoma is 53.1% for male patients and 59.3% for female patients. The difference in survival is significant (p = 0.035). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Overall survival curves according to gender of pathologic stage I in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage I in adenocarcinoma is 78.6% for male patients and 90.0% for female patients (p = ). The 5-year survival rate for pathologic stage I in nonadenocarcinoma is 65.4% for male patients and 72.8% for female patients (p = 0.058). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Overall survival curves according to gender of pathologic stage II in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage II in adenocarcinoma is 47.5% for male patients and 57.5% for female patients (p = 0.018). The 5-year survival rate for pathologic stage II in nonadenocarcinoma is 53.5% for male patients and 61.9% for female patients (p = 0.28). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 Disease-specific survival curves based on gender. The 5-year survival rates of female (n = 3890) and male (n = 7131) patients are 79.2 and 64.9%, respectively. The difference in survival between the genders is significant (p = ). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

8 FIGURE 7 Disease-specific survival curves according to gender in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for adenocarcinoma is 67.5% for male patients and 80.8% for female patients. The difference in survival is significant (p = ). The 5-year survival rate for nonadenocarcinoma is 61.6% for male patients and 66.3% for female patients. The difference in survival is not significant (p = 0.17). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

9 FIGURE 8 Disease-specific survival curves according to gender for pathologic stage I in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage I in adenocarcinoma is 85.3% for male patients and 93.5% for female patients (p = ). The 5-year survival rate for pathologic stage I in nonadenocarcinoma is 77.1% for male patients and 81.9% for female patients (p = 0.14). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

10 FIGURE 9 Disease-specific survival curves according to gender for pathologic stage II in adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year survival rate for pathologic stage II in adenocarcinoma is 53.4% for male patients and 60.0% for female patients (p = 0.087). The 5-year survival rate for pathologic stage II in nonadenocarcinoma is 61.1% for male patients and 69.3% for female patients (p = 0.42). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181f1923b) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study "

Similar presentations

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004  Tomohiko.

Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004  Tomohiko.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers  Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers  Hisao Asamura, MD, Tomoyuki Goya, MD, Yoshihiko Koshiishi, MD, Yasunori.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Results of Surgical Treatment for Patients with Small Cell Lung Cancer
Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD 

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD 
Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients  Camilla Maria T. Sagerup, MD, Milada.

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients  Camilla Maria T. Sagerup, MD, Milada.
Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer  Kyohei Masai, MD, Hiroyuki Sakurai,

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer  Kyohei Masai, MD, Hiroyuki Sakurai,
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection  Takeshi Hanagiri, MD, PhD, Kenji Sugio,

Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection  Takeshi Hanagiri, MD, PhD, Kenji Sugio,
Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database  Tetsuya Mizuno, MD, Meinoshin.

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database  Tetsuya Mizuno, MD, Meinoshin.

Similar presentations

Ads by Google